1. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Number of Hedge Fund Holders: 29
Stock Price: $3.32
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million. The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, compared with $753.9 million at the end of 2025, while maintaining expectations that its cash runway will extend into early 2028. CEO Najat Khan stated that the company continues seeing strong execution across its portfolio, including encouraging initial safety and pharmacokinetic data from REC-1245 and the first patient dosing in REC-4539. Management emphasized that the progress demonstrates the company’s ability to translate biological and chemical insights generated by its AI-driven platform into differentiated clinical-stage programs.
Earlier, on April 30, JPMorgan Chase & Co. lowered its price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $10 from $11 while maintaining an Overweight rating on the shares. The firm’s continued positive stance reflects confidence in the company’s long-term AI-enabled drug discovery platform despite near-term financial pressures and ongoing clinical development costs.
Recursion Pharmaceuticals is a clinical-stage TechBio company that integrates artificial intelligence, machine learning, and automation to industrialize drug discovery and development. Founded in 2013 and headquartered in Salt Lake City, the company focuses on decoding biology to identify treatments for rare diseases, oncology, and other areas with significant unmet medical needs. Its proprietary platform combines large-scale biological data analysis with advanced automation to accelerate therapeutic discovery.
The company’s substantial cash position and expanding clinical pipeline may provide flexibility to continue advancing multiple AI-driven drug programs despite ongoing development expenses.
While we acknowledge the potential of RXRX as an unrivaled penny stock, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 8 Best Energy Infrastructure Stocks That Will Skyrocket and 10 Tech Stocks That Could Make You a Millionaire.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
